Skip to search boxSkip to navigationSkip to main content

L-Buthionine (S,R) sulfoximine depletes hepatic glutathione but protects against ethanol-induced liver injury

  • Terrence M. Donohue(corresponding author)
    ,
  • ,
  • Sandra L. Todero
    ,
  • Ronda L. White
    ,
  • Kusum K. Kharbanda
    ,
  • Amin A. Nanji
*Corresponding author for this work
  • University of Nebraska Medical Center
    ,
  • Department of Veterans Affairs
    ,
  • Dalhousie University
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Background: L-Buthionine (S,R) sulfoximine (BSO) is an inhibitor of glutathione biosynthesis and has been used as an effective means of depleting glutathione from cells and tissues. Here we investigated whether treatment with BSO enhanced ethanol-induced liver injury in mice. Methods: Female C57Bl/6 mice were pair fed with control and ethanol-containing liquid diets in which ethanol was 29.2% of total calories. During the final 7 days of pair feeding, groups of control-fed and ethanol-fed mice were given 0, 5 or 7.6 mM BSO in the liquid diets. Results: Compared with controls, ethanol given alone decreased total liver glutathione. This effect was exacerbated in mice given ethanol with 7.6 mM BSO, causing a 72% decline in hepatic glutathione. While ethanol alone caused no decrease in mitochondrial glutathione, inclusion of 7.6 mM BSO caused a 2-fold decline compared with untreated controls. l-Buthionine (S,R) sulfoximine did not affect ethanol consumption, but serum ethanol levels in BSO-treated mice were nearly 6-fold lower than in mice given ethanol alone. The latter decline in serum ethanol was associated with a significant elevation in the specific activities of cytochrome P450 2E1 and alcohol dehydrogenase in livers of BSO-treated animals. Ethanol consumption caused a 3.5-fold elevation in serum alanine aminotransferase levels but the enzyme fell to control levels when BSO was included in the diet. l-Buthionine (S,R) sulfoximine administration also attenuated ethanol-induced steatosis, prevented the leakage of lysosomal cathepsins into the cytosol, and prevented the ethanol-elicited decline in proteasome activity. Conclusions: l-Buthionine (S,R) sulfoximine, administered with ethanol, significantly depleted hepatic glutathione, compared with controls. However, despite the decrease in hepatic antioxidant levels, liver injury by ethanol was alleviated, due, in part, to a BSO-elicited acceleration of ethanol metabolism.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1053-1060 (8 pages)

Journal (Volume, Issue Number)

Alcoholism: Clinical and Experimental Research (Volume 31, Issue 6)

Publication milestones

  • Published - 06/2007

Publication status

Published - 06/2007

ISSN

0145-6008

Publication IDs

  • Scopus: 34248644030
  • PubMed: 17428293
  • ORCID: /0000-0001-5315-2444/work/156540563

Publication metrics

Metrics

Scopus
citations
Fractional count
1
Fractional count
0.14
Fractional count
6
Fractional count
0.86
Fractional count
1
Fractional count
1
SciVal
citations
22
SciVal
FWCI
0.59
SciVal
Author count
7
SciVal
Paper percentile
75

PlumX, opens in new tab

Captures
13
Citation count
27

Funding Details

FunderFunding number
NIAAA
R01AA009384